Platinum’ derivates are antineoplastic agents widely adopted for their efficacy for the treatment of many pediatric cancers. The use of cisplatin has positively influenced the results of the cure of different childhood malignancies. However, cisplatin-based treatments are limited by the risk of severe and progressive toxicities, such as oto- or nephrotoxicity, that can be more serious in very young children expecially when high cumulative doses and/or radiotherapy is administered. A correct knowledge of the cisplatin’ pharmacological features might be of interest for clinicians in order to manage its potential toxicities. Based on the positive trend in the cure of children with cancer, it is crucial that all children receiving cisplatin-based chemotherapy have and appropriate and long-term follow-up to improve their quality of life.
CITATION STYLE
Ruggiero, A., Trombatore, G., Triarico, S., Capozza, M. A., Coccia, P., Attina, G., … Maurizi, P. (2019). Cisplatin toxicity in children with malignancy. Biomedical and Pharmacology Journal, 12(4), 1603–1611. https://doi.org/10.13005/bpj/1791
Mendeley helps you to discover research relevant for your work.